Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | TRIM24 | O15164 | 6/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | GPR39 | O43194 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26813009 | 0.83 | MAPK1 (0.43) | TDP1MAPK1MAPTGPR39BRD4 | |
| SCHEMBL26812931 | 0.83 | MAPK1 (0.45) | TDP1MAPK1MAPTGPR39BRD4 | |
| SCHEMBL24310819 | 0.82 | MAPK1 (0.47) | TDP1MAPK1MAPTGPR39BRD4 | |
| SCHEMBL24310808 | 0.82 | MAPK1 (0.46) | TDP1MAPK1MAPTGPR39CYP1A2 | |
| SCHEMBL26806813 | 0.79 | MAPT (0.61) | TDP1MAPK1LMNAMAPTKDM4E | |
| SCHEMBL26813002 | 0.79 | GPR39 (0.53) | TDP1MAPK1LMNAMAPTKDM4E | |
| SCHEMBL26813023 | 0.79 | MAPT (0.58) | TDP1TRIM24MAPK1LMNAMAPT | |
| SCHEMBL24309685 | 0.79 | MAPT (0.47) | TDP1MAPK1MAPTGPR39BRD4 | |
| SCHEMBL26812924 | 0.78 | MAPK1 (0.43) | TDP1TRIM24MAPK1MAPTGPR39 | |
| SCHEMBL26812951 | 0.78 | MAPK1 (0.47) | TDP1MAPK1LMNAMAPTGPR39 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | TDP1 4534/4885TRIM24 3261/4885MAPK1 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.